Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab.
Skvortsova
Ira
I
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D000068818:Cetuximab; D003131:Combined Modality Therapy; D006801:Humans; D018384:Oxidative Stress / Q000528:radiation effects*; D011836:Radiation Tolerance; D011855:Radiodermatitis / Q000378:metabolism / Q000473:pathology*; D017382:Reactive Oxygen Species / Q000528:radiation effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D017382:Reactive Oxygen Species; D000068818:Cetuximab